Literature DB >> 27402431

Regulation and role of ERK phosphorylation in glial cells following a nigrostriatal pathway injury.

Dan Li1, Lei Tong1, Hitoshi Kawano2, Nan Liu1, Hong-Jing Yan1, Liang Zhao1, Hong-Peng Li3.   

Abstract

This study was undertaken to examine the function of extracellular signal-regulated kinase (ERK) signaling pathway on the proliferation and activation of microglia/macrophage and astrocytes after brain injury in mice. The result of Western blot showed that p-ERK was immediately activated after injury (<4h), but the duration was short (<4 days). According to immunofluorescence double staining, it was found that at 4 and 8h after injury, p-ERK was expressed in microglia/macrophages, and that more cells were co-expressed by p-ERK and IBA-1 (microglia/macrophage marker) at 8h; at days 1 and 4, p-ERK was expressed in astrocytes, and more cells were co-expressed by p-ERK and GFAP (astrocyte marker) at day 4. After injury, the mice were injected with U0126 (MAPK/ERK signaling pathway inhibitor) via the femoral vein. Compared with those injected with DMSO, the cell number co-expressed by p-ERK and IBA-1 or GFAP significantly decreased (P<0.05). The increase of microglia/macrophage and astrocyte caused by injury was remitted, and the positive cell number significantly decreased (P<0.05). Western blot showed that the expression quantity of IBA-1 and GFAP significantly decreased (P<0.05). Furthermore, the ERK signaling pathway was involved in the proliferation and activation of the two glial cells types and improved long-term neurobehavioral function after brain injury. Therefore, the exploration of the formation mechanism of glial scar after injury and further research on the therapeutic method of neural regeneration are essential.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Astrocyte; ERK signal pathway; Microglia/macrophage; Nigrostriatal pathway injury; U0126

Mesh:

Substances:

Year:  2016        PMID: 27402431     DOI: 10.1016/j.brainres.2016.07.008

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Alteration of the neuronal and glial cell profiles in Neu1-deficient zebrafish.

Authors:  Asami Ikeda; Chiharu Yamasaki; Yurina Kubo; Yudai Doi; Mayu Komamizu; Masaharu Komatsu; Kazuhiro Shiozaki
Journal:  Glycoconj J       Date:  2022-07-25       Impact factor: 3.009

2.  Knockdown of PAR2 alleviates cancer-induced bone pain by inhibiting the activation of astrocytes and the ERK pathway.

Authors:  Yiting Tang; Yupeng Chen; Mingzhu Yang; Qiuhui Zheng; Yaoyuan Li; Yanju Bao
Journal:  BMC Musculoskelet Disord       Date:  2022-05-30       Impact factor: 2.562

3.  Interactions between Sirt1 and MAPKs regulate astrocyte activation induced by brain injury in vitro and in vivo.

Authors:  Dan Li; Nan Liu; Hai-Hua Zhao; Xu Zhang; Hitoshi Kawano; Lu Liu; Liang Zhao; Hong-Peng Li
Journal:  J Neuroinflammation       Date:  2017-03-29       Impact factor: 8.322

4.  Correlation of TGN-020 with the analgesic effects via ERK pathway activation after chronic constriction injury.

Authors:  Liang Zhao; Dan Li; Nan Liu; Lu Liu; Zhuo Zhang; Chao Gao; Hitoshi Kawano; Fang-Yuan Zhou; Hong-Peng Li
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

5.  Pretreatment with AM1241 Enhances the Analgesic Effect of Intrathecally Administrated Mesenchymal Stem Cells.

Authors:  Junran Xie; Jinxuan Ren; Na Liu; Chengwei Wu; Dongju Xiao; Huanyu Luo; Jingxian Du
Journal:  Stem Cells Int       Date:  2019-09-10       Impact factor: 5.443

6.  Batroxobin inhibits astrocyte activation following nigrostriatal pathway injury.

Authors:  Zhuo Zhang; Xue Bao; Dan Li
Journal:  Neural Regen Res       Date:  2021-04       Impact factor: 5.135

Review 7.  Multiple sclerosis is linked to MAPKERK overactivity in microglia.

Authors:  George J A Ten Bosch; Jolande Bolk; Bert A 't Hart; Jon D Laman
Journal:  J Mol Med (Berl)       Date:  2021-05-05       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.